Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma
Clinical trial NCT03644550 · TERMINATED
Trial details
- NCT number
- NCT03644550
- Sponsor
- National Cancer Institute (NCI)
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-04
- Primary completion
- 2020-08-05
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.